Information Provided By:
Fly News Breaks for October 10, 2019
Oct 10, 2019 | 14:55 EDT
Citi analyst Yigal Nochomovitz raised his price target on ProQR Therapeutics to $40 from $34, stating that he disagree's with the market's initial take on the company's updated data on sepofarsen. Given his view that the 12-month data validate the treatment benefits observed at 3 months, Nochomovitz increased his odds on the success for sepofarsen in patients with Leber's congenital amaurosis 10 to 70% from 50% and keeps his Buy rating on the stock. In afternoon trading, ProQR shares are down 26c, or 4%, to $5.95.
News For PRQR From the Last 2 Days
There are no results for your query PRQR